Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Research backs CKD inclusion in the QOF

By Nigel Praities

Chasing chronic kidney disease targets in a structured manner has quantifiable benefits for the health of patients, a trial by researchers including the Government's renal tsar, Dr Donal O'Donoghue, concludes.

The research provides the first concrete evidence to support addition of CKD to the QOF, with structured management slowing the rate of kidney decline and modifying cardiovascular risk factors.

Dr O'Donoghue's study, conducted in West Lincolnshire PCT, identified more than 480 patients with chronic kidney disease stages four and five using automated systems to derive eGFR from serum creatinine tests.

After nine months in the programme, there were significant improvements in patient outcomes, with total cholesterol down from 4.6 to 4.2mmol/l and diastolic blood pressure down from 76 to 71mmHg.

The research appears online in the Nephrology Dialysis Transplantation journal.

QOF

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say